FTC investigation prompts Teva request for removal of patents from Orange Book

After a challenge from the Federal Trade Commission, Teva (TEVA) Pharmaceuticals has requested that the Food and Drug Administration remove more than 200 improper patent listings from the FDA’s Orange Book, the FTC announced. “The FTC sent a series of warning letters in May 2025 to Teva and several other pharmaceutical companies, which have also withdrawn most of the disputed listings,” the FTC stated.